32,728 Shares in AstraZeneca PLC $AZN Bought by White Lighthouse Investment Management Inc.

Key Points

• White Lighthouse Investment Management Inc. acquired 32,728 shares of AstraZeneca PLC valued at approximately $2,287,000 during the 2nd quarter.
• AstraZeneca reported earnings of $1.09 EPS for the last quarter, meeting analysts' expectations, with revenues of $14.46 billion, up 16.1% year-over-year.
• The company recently declared a dividend yield of 200.0%, with a payout ratio of 37.97% as of the latest semi-annual dividend declaration.

White Lighthouse Investment Management Inc. acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 32,728 shares of the company's stock, valued at approximately $2,287,000.

Several other hedge funds have also bought and sold shares of the company. Patten Group Inc. increased its position in AstraZeneca by 27.9% during the second quarter. Patten Group Inc. now owns 66,492 shares of the company's stock worth $4,646,000 after buying an additional 14,507 shares during the last quarter. Exencial Wealth Advisors LLC lifted its position in shares of AstraZeneca by 5.3% in the second quarter. Exencial Wealth Advisors LLC now owns 32,714 shares of the company's stock valued at $2,286,000 after buying an additional 1,661 shares during the last quarter. D.A. Davidson & CO. boosted its stake in shares of AstraZeneca by 3.1% during the 2nd quarter. D.A. Davidson & CO. now owns 37,163 shares of the company's stock worth $2,597,000 after acquiring an additional 1,109 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of AstraZeneca by 37.7% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 23,476 shares of the company's stock worth $1,640,000 after acquiring an additional 6,424 shares during the last quarter. Finally, Whittier Trust Co. raised its stake in AstraZeneca by 20.9% in the 2nd quarter. Whittier Trust Co. now owns 40,073 shares of the company's stock valued at $2,800,000 after acquiring an additional 6,929 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AstraZeneca stock opened at $83.22 on Wednesday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The stock has a market cap of $258.10 billion, a PE ratio of 31.29, a P/E/G ratio of 1.55 and a beta of 0.36. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $86.57. The business's 50-day moving average price is $80.58 and its two-hundred day moving average price is $74.03.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts' consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. During the same quarter in the prior year, the business earned $1.24 earnings per share. The business's revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were paid a $0.505 dividend. This represents a dividend yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca's dividend payout ratio is presently 37.97%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a "buy (b)" rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Berenberg Bank set a $97.00 price objective on AstraZeneca in a report on Wednesday, July 9th. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a "hold" rating to a "sell" rating in a research report on Thursday, October 16th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.